Elevated uric acid is not just a gout risk marker. It is a signal of fructose-driven ATP depletion, metabolic syndrome, insulin resistance, and impaired renal acid handling. Understanding purine metabolism, xanthine oxidase, and why humans accumulate uric acid that other mammals excrete reveals a clinically important story that most blood panels miss.
Gout has a reputation as a wealthy man’s disease — the result of too much port wine and rich food at the dining table of prosperity. This framing has persisted long past its usefulness. Gout is the clinical endpoint of uric acid accumulation, and the modern understanding of uric acid places it at the centre of metabolic syndrome, cardiovascular disease, kidney disease, and insulin resistance — a much more significant story than its traditional association with painful big toes would suggest.
Understanding where uric acid comes from, why it accumulates, and what this accumulation does to physiology is increasingly important in functional health practice. Elevated uric acid is not just a gout risk marker. It is a metabolic signal.
Purines are the nitrogen-containing bases of nucleotides: adenine and guanine (in DNA and RNA), plus ATP, ADP, AMP, NAD+, CoA, and other critical metabolic molecules. They are obtained from diet (organ meats, shellfish, red meat, beer, anchovies) and synthesised endogenously via the de novo purine synthesis pathway.
Purine degradation: Purines → hypoxanthine → xanthine → uric acid. The enzyme xanthine oxidase catalyses the final two steps. Allopurinol (the standard gout medication) is a xanthine oxidase inhibitor — it blocks uric acid production at this step.
Uric acid fate: In humans (and great apes), uric acid is the final end product of purine metabolism. Most mammals have uricase, an enzyme that breaks down uric acid to allantoin (water-soluble, easily excreted). Humans lost uricase approximately 15 million years ago via a genetic mutation. This evolutionary quirk means we accumulate uric acid that other mammals excrete efficiently.
Excretion: 70% of uric acid is excreted by the kidneys. 30% enters the gut where bacteria degrade it (uricolysis). Any impairment of renal excretion — from kidney disease, diuretics, low-grade aciduria — raises serum uric acid.
The most important and least discussed driver of elevated uric acid in modern populations is not dietary purine intake — it is fructose consumption. The metabolic pathway explains why.
Glucose metabolism is regulated: hexokinase is saturated at physiological glucose concentrations, preventing runaway glucose phosphorylation. Fructose metabolism bypasses this regulation: fructokinase phosphorylates fructose to fructose-1-phosphate without regulation, rapidly depleting intracellular ATP (adenosine triphosphate) as phosphate groups are consumed. Depleted ATP is degraded through the purine pathway: ATP → ADP → AMP → IMP → hypoxanthine → xanthine → uric acid.
Each molecule of fructose consumed generates uric acid through ATP depletion — regardless of dietary purine content. This is why high-fructose corn syrup in the food supply and the dramatic increase in fruit juice consumption correlate directly with the rising prevalence of hyperuricaemia and gout in populations that are not eating significantly more organ meats or shellfish.
Raised serum uric acid (above typical lab limits of about 360 µmol/L, 6.0 mg/dL, in women and 420 µmol/L, 7.1 mg/dL, in men) is associated in observational studies with: hypertension (uric acid reduces nitric oxide bioavailability in the endothelium), insulin resistance (uric acid impairs insulin signalling in multiple tissues), non-alcoholic fatty liver disease (fructose-driven uric acid production co-occurs with hepatic fat accumulation), chronic kidney disease (uric acid crystals deposit in renal tubules), and cardiovascular disease (endothelial dysfunction and inflammation).
These associations are bidirectional in some cases — insulin resistance raises uric acid, and uric acid worsens insulin resistance — creating a self-reinforcing cycle. Whether uric acid drives cardiometabolic disease or mainly travels with it is still debated, so I treat it as a marker worth acting on through diet, not as proof of cause.
Uric acid kidney stones form in acidic urine (pH below 5.5) where uric acid is relatively insoluble. Dietary patterns that produce high acid load (high PRAL) combined with high purine intake create the perfect storm for uric acid crystallisation in the renal collecting system. This is why the acid-base balance discussion from the previous post connects directly here: urinary alkalinisation through dietary pattern change (potassium, vegetables, reduced refined grains) reduces uric acid stone risk alongside its other benefits.
Reduce: fructose and high-fructose corn syrup (read labels), fruit juice, alcohol (especially beer — highest purine content per serving), organ meats, shellfish, anchovies, sardines. Increase: water (dilutes and promotes renal excretion), cherry extract (reduces inflammation and may reduce uric acid), coffee (epidemiologically associated with lower uric acid). Dairy proteins promote renal uric acid excretion.
Diuretics (thiazides and loop diuretics compete with uric acid for renal excretion — extremely common in hypertension treatment). Low-dose aspirin. Ciclosporin. Pyrazinamide. Niacin at high doses. All reduce renal uric acid clearance. Relevant to consider when elevated uric acid appears alongside these medications.
De novo purine synthesis requires folate (5,10-methyleneTHF). MTHFR variants that impair folate metabolism can paradoxically reduce de novo purine synthesis capacity while elevating homocysteine. The folate-purine-methylation triangle is clinically relevant in complex presentations with both elevated homocysteine and uric acid.
Uric acid is a metabolic exhaust marker. It tells you that purines are being degraded at a high rate — from dietary purine load, from fructose-driven ATP depletion, from rapid cell turnover, or from impaired renal clearance. The question is always which engine is producing the exhaust.
Blood chemistry: Serum uric acid (read against the lab range; there’s no agreed optimum outside gout. In gout, NICE NG219 sets a treatment target below 360 µmol/L, 6 mg/dL, or below 300 µmol/L, 5 mg/dL, with tophi or continuing flares), kidney function (eGFR, creatinine — uric acid rises as GFR falls), fasting glucose and insulin (insulin resistance connection), TG and TG:HDL (metabolic syndrome context). Urinary pH: Consistently below 5.5 — uric acid stone risk environment. Targetable through dietary acid load reduction. Metabolomix+ OAT: Uric acid on some OAT panels; more importantly, xanthine and hypoxanthine as upstream purine degradation markers. Orotate (urea cycle marker that elevates alongside some purine synthesis states). Dietary assessment: Fructose intake from all sources (fruit juice, HFCS, added sugar in processed foods) is often dramatically underestimated. A detailed dietary analysis commonly reveals fructose loads of 50–80g daily in clients with elevated uric acid who report “healthy” diets.
Ask the DH Concierge — trained on nearly forty years of working with people and the full biochemical foundation of the TDG approach.
Ask the Concierge → Book a free 20-minute call